Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandospirone plus amlodipine for anxiety with mild-to-moderate essential hypertension
ChiCTR1900026453Phase 4Not yet recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tandospirone in essential hypertension and anxiety disorder (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoint: Control rate of hypertension at end of study. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
tandospirone
03
Conditions
essential hypertensionanxiety disorder
Beyond the preview
Go deeper on ChiCTR1900026453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026453.